HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $2 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.
June 14, 2023 | 10:22 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akebia Therapeutics (NASDAQ:AKBA) receives a Neutral rating from HC Wainwright & Co. analyst Ed Arce, with a maintained $2 price target.
The news of HC Wainwright & Co. analyst Ed Arce reiterating a Neutral rating on Akebia Therapeutics and maintaining a $2 price target is directly related to the company. However, since the rating is neutral and the price target is maintained, it is not expected to have a significant short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100